Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recruiting · NCT05577819 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF | Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, diastolic heart failure, familial amyloid neuropathy, heart disorder, heart failure, metabolic disease, proteostasis deficiencies | Recruiting | Not applicable | 2026-09-01 | NCT05577819 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Akcea Therapeutics | 3 |
| Alnylam Pharmaceuticals | 27 |
| Eidos Therapeutics, a BridgeBio company | 6 |
| Massachusetts General Hospital | 758 |
| Pfizer | 431 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |